These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9239514)

  • 1. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme.
    Funato T; Ishii T; Kanbe M; Scanlon KJ; Sasaki T
    In Vivo; 1997; 11(3):217-20. PubMed ID: 9239514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reversal of drug resistance in human cancer cells by anti-oncogenes].
    Funato T
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):395-400. PubMed ID: 9063474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
    Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
    Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Circumventing multidrug resistance in human cancer by anti-ribozyme].
    Funato T
    Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circumventing drug resistance in human tumors by antisense ribozyme].
    Funato T
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):336-42. PubMed ID: 8109989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells.
    Funato T; Ishii T; Kambe M; Scanlon KJ; Sasaki T
    Cancer Gene Ther; 2000 Mar; 7(3):495-500. PubMed ID: 10766356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene.
    Nagata J; Kijima H; Hatanaka H; Asai S; Miyachi H; Abe Y; Yamazaki H; Nakamura M; Watanabe N; Mine T; Kondo T; Scanlon KJ; Ueyama Y
    Int J Oncol; 2002 Nov; 21(5):1021-6. PubMed ID: 12370750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
    Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.
    Dorai T; Goluboff ET; Olsson CA; Buttyan R
    Anticancer Res; 1997; 17(5A):3307-12. PubMed ID: 9413164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribozyme-targeting procathepsin D and its effect on invasion and growth of breast cancer cells: an implication in breast cancer therapy.
    Vashishta A; Ohri SS; Proctor M; Fusek M; Vetvicka V
    Int J Oncol; 2007 May; 30(5):1223-30. PubMed ID: 17390025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
    Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
    Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas.
    Funato T; Yoshida E; Jiao L; Tone T; Kashani-Sabet M; Scanlon KJ
    Adv Enzyme Regul; 1992; 32():195-209. PubMed ID: 1496917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
    Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
    Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constructing the eukaryotic expression vector to study preliminarily the functions of hammerhead ribozyme targeting base excision repair gene HOGG1.
    Zhang ZZ; Zhang Q; Wu M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):165-70. PubMed ID: 16608066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribozyme targeted on HPV16E6 mRNA induced apoptosis on human cervical carcinoma CaSKi cells.
    Zheng YF; Zhang JR
    Ai Zheng; 2003 May; 22(5):458-62. PubMed ID: 12753702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
    Davies G; Watkins G; Mason MD; Jiang WG
    Prostate; 2004 Sep; 60(4):317-24. PubMed ID: 15264243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis.
    Orlandi L; Binda M; Folini M; Bearzatto A; Villa R; Daidone MG; Zaffaroni N
    Prostate; 2003 Feb; 54(2):133-43. PubMed ID: 12497586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of c-myc in regulating mdr1 gene expression in tumor cell line KB.
    He Y; Zhang J; Zhang J; Yuan Y
    Chin Med J (Engl); 2000 Sep; 113(9):848-51. PubMed ID: 11776085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance.
    Cimbora-Zovko T; Ambriović-Ristov A; Loncarek J; Osmak M
    Eur J Pharmacol; 2007 Mar; 558(1-3):27-36. PubMed ID: 17234182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.